Virtual Symposium (CME concluded): The Potassium Dilemma in HF and CKD: Challenges and Advancements in the Management of Hyperkalemia

Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia. Although the short-term management of hyperkalemia can be very effective, the utility of current strategies to manage hyperkalemia is limited, with no long-term outcome data to guide in the management of this condition. This symposium will provide clinicians with clinical evidence on the new potassium-binding agents for the long-term management of hyperkalemia to improve guideline adherence and help clinicians move toward optimizing guideline-directed medical therapy for hyperkalemic patients with HF and CKD.

Hyperkalemia in HF and CKD: Current Challenges

Presenter: Peter A. McCullough, MD, MPH

Evolving Treatment Options for Hyperkalemia

Presenter: Biff F. Palmer, MD

Challenging Patient Case: Management of Hyperkalemia in a Hypertensive Patient with CKD and T2DM

Presenter: Matthew R. Weir, MD

Panel: All Faculty

Audience Q&A

Chairperson: George L. Bakris, MD

Panel: All Faculty